UCB (OTCMKTS:UCBJF) Reaches New 12-Month Low – Here’s Why

UCB SA (OTCMKTS:UCBJF)’s share price reached a new 52-week low on Thursday. The stock traded as low as $219.60 and last traded at $219.60, with a volume of 1 shares traded. The stock had previously closed at $236.94.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Piper Sandler reissued a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Jefferies Financial Group raised UCB to a “hold” rating in a research note on Monday, August 3rd. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy”.

UCB Trading Down 7.3%

The company has a 50-day simple moving average of $252.82 and a two-hundred day simple moving average of $279.78. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for severe diseases, particularly in immunology and neurology. The company’s research and development activities target conditions such as inflammatory disorders, epilepsy, and other diseases affecting the central nervous system.

UCB’s portfolio includes Bimzelx (bimekizumab) for certain inflammatory conditions, Cimzia (certolizumab pegol) for immune-mediated diseases, and Fintepla (fenfluramine), Briviact (brivaracetam), Keppra (levetiracetam), and Nayzilam (midazolam) for seizure-related disorders.